Work

GLIX1: A first-in-class oral molecule targeting the DNA damage response by restoring TET2 activity.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.e14072

Authors: Adam Robertson, Guro Kristoffersen, Sandra Cantilena, Claudia Katharina Petritsch, Ella Sorani

Institutions: Stanford Medicine, Stanford University, BioLineRx Ltd. (Israel)

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162685159

Cites:

Cited by:

Related to: